Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 7 March 2024, 10:24 HKT/SGT
Share:
    

Source: NEC Corporation
NEC named to list of Top 100 Global Innovators by Clarivate for 13th consecutive year

TOKYO, Mar 7, 2024 - (JCN Newswire) - NEC Corporation (TSE: 6701) has been named to the list of Top 100 Global Innovators™ 2024 by Clarivate Plc., which selects companies and organizations that "sit at the very top of the global innovation ecosystem, with the most consistent above-the-bar innovation performance." This is the 13th* consecutive year that NEC has been selected for the award.



Clarivate is one of the world's largest database companies, serving more than 45,000 government and academic institutions, corporations, and law firms in more than 200 countries and territories. The Clarivate Top 100 Global Innovators 2024 is an award presented to companies and organizations that have filed at least 100 patents in the last five years, and who are evaluated and ranked based on Clarivate’s proprietary data, as well as the following four factors: Influence, Success, Investment, and Rarity.In addition to strengthening intellectual property in technology areas that drive growth businesses, NEC is actively using its intellectual property for advancing co-creation with stakeholders. Going forward, NEC will continue to create new social value by utilizing intellectual property.

*Only 18 organizations in the world have been selected for this award for 13 consecutive years.ShareNEC's intellectual property activities.

URL: https://www.nec.com/en/global/intellectual-property/index.html
Top 100 Global Innovators 2024: https://clarivate.com/top-100-innovators/
Clarivate Press Release: https://clarivate.com/newsroom/

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.




Topic: Press release summary
Source: NEC Corporation

Sectors: Cloud & Enterprise
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation
Apr 24, 2024 12:25 HKT/SGT
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 22, 2024 14:09 HKT/SGT
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 11, 2024 14:10 HKT/SGT
DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission
Apr 10, 2024 12:36 HKT/SGT
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Apr 8, 2024 12:45 HKT/SGT
NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
Mar 25, 2024 09:08 HKT/SGT
NEC develops marketing strategy planning & effectiveness simulation technology using generative AI
Mar 22, 2024 07:38 HKT/SGT
NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber
Mar 21, 2024 09:02 HKT/SGT
NEC and Tokyo Medical and Dental University use AI to assist self-care for chronic lower back pain
Mar 20, 2024 14:30 HKT/SGT
NEC and Skyloom to Pioneer 100 Gbps Space Optical Communications, Transforming Global Internet Connectivity
Mar 5, 2024 08:05 HKT/SGT
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: